Abstract
The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.
MeSH terms
-
Acids / chemistry
-
Amides / chemistry
-
Carboxylic Acids / chemistry
-
Chemistry, Pharmaceutical / methods*
-
Crystallization / methods
-
Crystallography
-
Drug Stability
-
Hydrogen Bonding
-
Molecular Structure
-
Organic Chemicals / chemistry
-
Pharmaceutical Preparations*
-
Phase Transition
-
Technology, Pharmaceutical / instrumentation
-
Technology, Pharmaceutical / methods*
Substances
-
Acids
-
Amides
-
Carboxylic Acids
-
Organic Chemicals
-
Pharmaceutical Preparations